Christopher B Ehrlich insider trades: eFFECTOR Therapeutics (EFTR) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christopher reports to the SEC
and 7 more companies
Open-market buys and sales
16 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 4, 2022 | EFTR | ↑ Buy | 346 | $0.57 | $197 | Direct | Oct 6, 2022 (2d) |
| Sep 26, 2022 | EFTR | ↑ Buy | 18,867 | $0.55 | $10K | Direct | Sep 27, 2022 (1d) |
| Feb 18, 2022 | EFTR | ↑ Buy | 3,000 | $4.40 | $13K | Direct | Feb 22, 2022 (4d) |
| Feb 9, 2022 | EFTR | ↑ Buy | 2,000 | $4.83 | $10K | Direct | Feb 10, 2022 (1d) |
| Feb 4, 2022 | EFTR | ↑ Buy | 6,000 | $5.13 | $31K | Direct | Feb 7, 2022 (3d) |
| Jan 27, 2022 | EFTR | ↑ Buy | 5,000 | $5.30 | $27K | Direct | Jan 31, 2022 (4d) |
| Jul 3, 2012 | TSRO | ↑ Buy | 444,444 | $13.50 | $6.0M | Direct | Jul 5, 2012 (2d) |
| Sep 21, 2011 | TSPT | ↑ Buy | 732,076 | $6.78 | $5.0M | Indirect | Sep 22, 2011 (1d) |
| Aug 6, 2010 | TSRX | ↑ Buy | 1,227,333 | $5.00 | $6.1M | Direct | Aug 10, 2010 (4d) |
| Apr 7, 2009 | BMTI | ↑ Buy | 941,177 | $8.50 | $8.0M | By InterWest Partner X, LP | Apr 8, 2009 (1d) |
| Dec 18, 2007 | ANSV | ↑ Buy | 1,905,581 | $4.05 | $7.7M | Direct | Dec 20, 2007 (2d) |
| Dec 18, 2007 | ANSV | ↑ Buy | 54,518 | $4.05 | $221K | By InterWest Investors Q VIII, L.P. | Dec 20, 2007 (2d) |
| Dec 18, 2007 | ANSV | ↑ Buy | 15,210 | $4.05 | $62K | By InterWest Investors VIII, L.P. | Dec 20, 2007 (2d) |
| Nov 15, 2007 | ETRM | ↑ Buy | 187,500 | $8.00 | $1.5M | By: InterWest Partners IX, LP | Nov 19, 2007 (4d) |
| May 15, 2006 | BMTI | ↑ Buy | 1,250 | $8.00 | $10K | Direct | May 16, 2006 (1d) |
| Feb 28, 2006 | CGTK | ↑ Buy | 2,200 | $9.02 | $20K | Direct | Mar 1, 2006 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Christopher B Ehrlich's insider trades
Christopher B Ehrlich is an insider at eFFECTOR Therapeutics (EFTR). Since Feb 28, 2006, Christopher has reported 16 open-market purchases worth $34.7M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (21 filings), other transactions (6 filings), conversions (5 filings), shares returned to the company (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EFTR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.